PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes.

Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with active pharmaceutical ingredients to enable the precise delivery of drugs at optimal release rates over durations ranging from days to months.

PolyPid’s lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

In addition, the company’s OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.